Published in Vaccine Weekly, January 14th, 2004
One of the important milestone for 2004 is expected to be the results from the BLP 25 Liposomal vaccine (L-BLP25) phase IIb study of 171 patients with non-small cell lung cancer. The final analysis is expected toward the end of Q1/2004, with results anticipated to be reported shortly thereafter. Biomira will also continue its analysis of data from its phase III Theratope vaccine trial and specifically the subset of women receiving hormonal therapy as part of their initial treatment. The objective here will be to discuss plans with the regulatory authorities, once the strategy has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly